Despite clearing the cardiovascular dishonor, Avandia will be voluntarily withdrawn
Avandia(rosiglitazone), a thiazolidinediones(TZD) diabetes drug, was able to avoid the issue of having cardiovascular side effects, but decided to withdraw the domestic market, though.
It seems very contrary to other TZD drugs, such as Takeda Pharmaceuticals Korea’s Actos and Chong Kun Dang’s Du...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
